Introduction Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are well-established therapeutic agents that exert potent glucose-lowering effects by stimulating insulin secretion, suppressing glucagon secretion in a glucose-dependent manner, and delaying gastric emptying ( Eating behavior is a critical determinant in T2D management ( Although these eating behavior patterns are hypothesized to influence the clinical efficacy of GLP-1RA therapy, direct evidence remains limited
Table 10 Results of a 26-week Trial of Liraglutide Injection as Add-on to Metformin and Thiazolidinedione in Adult Patients with Type 2 Diabetes Mellitus a Liraglutide Injection Compared to Placebo Both With or Without metformin and/or Sulfonylurea and/or Pioglitazone and/or Basal or Premix insulin in Patients with Type 2 Diabetes Mellitus and Moderate Renal Impairment In this 26-week, double-blind, randomized, placebo-controlled, parallel-group trial in adult patients with type 2 diabetes mellitus, 279 patients with moderate renal impairment, as per MDRD formula (eGFR 30-59 mL/min/1.73 m2), were randomized to liraglutide injection or placebo once daily
For serious research, a dedicated lab refrigerator is always the superior choice
Diffuse pharmacophoric domains of vasoactive intestinal peptide (VIP) and further insights into the interaction of VIP with the N-terminal ectodomain of human VPAC1 receptor by photoaffinity labeling with [Bpa6]-VIP
Gender-dependent effects of maternal immune activation on the behavior of mouse offspring
Translation from prostate cancer spacer experience to cervical cancer The widespread clinical adoption of hydrogel spacers in prostate cancer brachytherapy offers a proven framework for translation to cervical cancer, providing both technical and regulatory guidance [190]
